SCHEMBL318644 — predicted protein targets

Predicted protein targets (top 15)

	gene	UniProt	supporting neighbours	confidence
▸	AR	P10275	2/20	0.37

▸	RIPK1	Q13546	1/20	0.36

▸	PIM2	Q9P1W9	9/20	0.35

▸	PIM1	P11309	8/20	0.35

▸	PIM3	Q86V86	7/20	0.35

▸	GABRG2	P18507	1/20	0.35

▸	GABRB3	P28472	1/20	0.35

▸	GABRA2	P47869	1/20	0.35

▸	ALOX5	P09917	1/20	0.35

▸	DHODH	Q02127	1/20	0.33

▸	ACVR1	Q04771	1/20	0.33

▸	KDM4E	B2RXH2	1/20	0.33

▸	ALDH1A1	P00352	1/20	0.33

▸	MAP2K3	P46734	1/20	0.33

▸	RECQL	P46063	1/20	0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL14902600	0.91	RIPK1 (0.36)	ARRIPK1PIM2PIM1PIM3
SCHEMBL327143	0.90	PIM2 (0.37)	ARRIPK1PIM2PIM1PIM3
SCHEMBL11909711	0.86	MEN1 (0.38)	PIM2PIM1PIM3KDM4EALDH1A1
SCHEMBL11907594	0.83	GABRG2 (0.39)	ARRIPK1PIM2PIM1PIM3
SCHEMBL11909713	0.81	MAP2K3 (0.33)	PIM2PIM1PIM3DHODHMAP2K3
SCHEMBL11907548	0.79	FFAR4 (0.41)	PIM2PIM1PIM3DHODHMAP2K3
SCHEMBL4436068	0.77	PIM2 (0.52)	ARPIM2PIM1PIM3
SCHEMBL11909552	0.77	LMNA (0.38)	PIM2PIM1PIM3GABRG2GABRB3
SCHEMBL11907553	0.74	FGFR2 (0.41)	PIM2PIM1PIM3DHODHKDM4E
SCHEMBL319370	0.74	AR (0.37)	ARPIM2PIM1PIM3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20140249135-A1	PIM KINASE INHIBITORS AND METHODS OF THEIR USE	NOVARTIS AG (CH)	2014-09-04	—	—	US	disclosed
US-8822497-B2	PIM kinase inhibitors and methods of their use	NOVARTIS AG (CH)	2014-09-02	—	—	US	disclosed
EP-2132177-B1	PIM KINASE INHIBITORS AND METHODS OF THEIR USE	NOVARTIS AG (CH)	2013-07-17	—	—	EP	disclosed
EP-2590968-A1	CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS	Novartis AG (CH)	2013-05-15	—	—	EP	disclosed
US-20130109682-A1	CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS	NOVARTIS AG (CH)	2013-05-02	—	—	US	disclosed
US-20130109682-A1	CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS	NOVARTIS AG (CH)	2013-05-02	—	—	US	disclosed
US-20130109682-A1	CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS	NOVARTIS AG (CH)	2013-05-02	—	—	US	disclosed
US-20120208815-A1	PIM KINASE INHIBITORS AND METHODS OF THEIR USE	NOVARTIS AG (CH)	2012-08-16	—	—	US	disclosed
WO-2012004217-A1	CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS	NOVARTIS AG (CH)	2012-01-12	—	—	WO	disclosed
WO-2012004217-A1	CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS	NOVARTIS AG (CH)	2012-01-12	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20130109682-A1	CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS	PIM1, GSK3A, GSK3B	AR 1402/4885RIPK1 658/4885PIM2 4/4885
US-20140249135-A1	PIM KINASE INHIBITORS AND METHODS OF THEIR USE	PIM1, PIM2, PIM3	AR 2314/4885RIPK1 351/4885PIM2 2/4885
US-20120208815-A1	PIM KINASE INHIBITORS AND METHODS OF THEIR USE	PIM1, PIM2, PIM3	AR 2314/4885RIPK1 351/4885PIM2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.